Humacyte (HUMA) Retained Earnings (2020 - 2026)

Humacyte (HUMA) has reported Retained Earnings for 7 consecutive years, with $812.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Retained Earnings rose 18.0% year-over-year to $812.5 million in Q2 2026; TTM through Jun 2026 was $812.5 million, a 18.0% increase from a year earlier, with the FY2025 full-year figure at $729.9 million, up 206.4% from the prior year.
• Retained Earnings was $812.5 million for Q2 2026 at Humacyte, up from $756.1 million in the prior quarter.
• Over five years, Retained Earnings peaked at $812.5 million in Q2 2026 and troughed at -$702.0 million in Q3 2025.
• A 5-year average of $330.1 million and a median of $546.4 million in 2023 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings soared 4140.55% in 2022 and tumbled 224.54% in 2024, its largest moves.
• Over 5 years, Retained Earnings stood at $543.5 million in 2022, then rose by 1.36% to $550.8 million in 2023, then plunged by 224.54% to -$686.0 million in 2024, then surged by 206.4% to $729.9 million in 2025, then climbed by 11.31% to $812.5 million in 2026.
• The last three Retained Earnings figures came in at $812.5 million (Q2 2026), $756.1 million (Q1 2026), and $729.9 million (Q4 2025), per Business Quant data.